A Phase 4 interventional study of Buprenorphine Transdermal System and Placebo Patch in Pain, Postoperative, Ankle Fracture Surgery and Opioid Use Disorder, sponsored by Jenna-Leigh Wilson. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Jenna-Leigh Wilson · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing buprenorphine in Pain, Postoperative — 3 open to participants now, 4 under way, none of them phase 3. Buprenorphine · Pain, Postoperative.
Among the 13 studies testing buprenorphine in Pain, Postoperative, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 4, and was the 11th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →3 of the 13 studies testing buprenorphine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Medical University of Silesia · Sites in Poland
Ages 18–75
Clínica Dávila · Sites in Chile
Ages 18+
By country, each count listing its studies:
Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 76 across the 13 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jenna-Leigh Wilson as lead sponsor.
Jenna-Leigh Wilson has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
3 of the studies testing buprenorphine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07733128Clínica DávilaAnalgesia With Transdermal Buprenorphine Patch in Adults Undergoing Video-Assisted Thoracoscopic Surgery | 2027-03 |
| NCT06949826Jenna-Leigh WilsonBuprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery | 2027-03 |
| NCT07434427Medical University of SilesiaComparison of the Efficacy and Safety of Intravenous Buprenorphine Administered Via PCA System Versus Oxycodone in the Management of Postoperative Pain After Video-Assisted Thoracoscopic Surgery | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies testing buprenorphine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery. Buprenorphine is an opioid with unique properties that may offer a way to reduce the number of patients that become addicted to opioids after surgery. Buprenorphine has good analgesic (painkilling) effects. It is also thought to be less addictive and cause less of a high than full-agonist opioids, like oxycodone and hydrocodone. This project's goal is to determine if transdermal buprenorphine can safely and effectively control pain after ankle fracture surgery. This study will be a pilot study, which sets the stage for future studies that investigate whether buprenorphine can reduce the rate that patients become addicted to opioids after surgery. This study's multidisciplinary team will divide patients into two groups. Participants in one group will be treated with a 7-day transdermal buprenorphine patch (where the buprenorphine is slowly absorbed through the skin over 7 days). Participants in the other group will be treated with a placebo patch. A placebo has no drug in it, it just looks like the buprenorphine patch. Aside from the buprenorphine patch or placebo patch, both groups' pain management plans will be the same as if they were not in the study. Over the first week after surgery, the investigators will measure the amount of full-agonist opioids (for example, oxycodone or hydrocodone) that participants consume, participants' pain scores, the frequency of side effects related to opioids, and the number of calls and patient portal messages to the clinic for uncontrolled pain. The investigators will also assess whether participants are continuing to use opioids 3 months after surgery for pain related to their ankle fracture.
Addictive full-agonist opioids, like oxycodone, remain a staple of post-operative analgesia after many types of surgery. However, perioperative exposure to opioid analgesics risks addiction in up to 7% of cases. Moreover, opioid overdoses kill over 80,000 in the United States (US) annually. Buprenorphine, a partial-agonist of the μ-opioid receptor and an antagonist of the κ-opioid receptor, may be able to safely function as a post-operative analgesic, reducing our reliance on full-agonist opioids post-operatively. Compared to full-agonist opioids, buprenorphine has a favorable safety profile. It has been hypothesized that buprenorphine's unique pharmacodynamics give it a lower addictive potential compared to full-agonist opioids. Moreover, it endows a ceiling on respiratory depression, has reduced dysphoric and psychotomimetic effects, and does not result in immunosuppression at therapeutic analgesic doses. International studies have suggested that transdermal buprenorphine is noninferior to tramadol, transdermal fentanyl, and oral celecoxib in the management of acute post-operative pain in opioid-naïve patients following orthopaedic surgery. However, the efficacy of buprenorphine for postoperative analgesia has never been studied in the United States, whose population has different beliefs and expectations surrounding pain control when compared to international populations. The major goal of this project is to determine the safety and efficacy of transdermal buprenorphine for postoperative analgesia, as a first step toward exploring the ability of buprenorphine to mitigate the incidence of opioid dependence in the postoperative setting.
This study will assess whether buprenorphine can reduce the use of full-agonist opioids following ankle fracture surgery. Approximately one in five opioid-naïve patients undergoing ankle fracture surgery continue to use opioids 3 to 6 months out from surgery, suggesting that this population is relatively susceptible to developing post-operative opioid dependence. The investigators will divide patients into two groups. One group will be treated with a 7-day transdermal buprenorphine patch. The other will be treated with a placebo patch. Both groups will otherwise receive a post-operative pain management regimen that is in accordance with the standard of care. The investigators hypothesize that participants treated with the buprenorphine patch will experience improved analgesia with the use fewer full-agonist opioids following ankle fracture surgery than those treated with the placebo patch. This hypothesis will be tested with the following aims.
Specific Aim 1: To measure the analgesic effect of buprenorphine on post-operative analgesia. In this Aim, the investigators will test the hypothesis that use of buprenorphine patches will reduce the average pain scores and consumption of full-agonist opioids after ankle fracture surgery. In sub-Aim 1.1, the investigators will quantify postoperative pain by monitoring participants' visual analog scale pain scores and full-agonist opioid consumption over the first post-operative week. In sub-Aim 1.2, the investigators will track the number of episodes of breakthrough pain in the hospital, the number of calls to the clinic with a chief complaint of uncontrolled pain, and the number of presentations to an emergency department for uncontrolled surgery-related pain.
Specific Aim 2: To examine the safety of buprenorphine as a post-operative analgesic following ankle fracture surgery. In this Aim, the investigators will test the hypothesis that participants treated with buprenorphine patches will experience fewer adverse events related to opioid exposure compared to those treated with placebo patches. The investigators will monitor for adverse effects of buprenorphine and full-agonist opioids, including respiratory depression, constipation, nausea, and vomiting. The investigators will track the number of presentations to an emergency department with a diagnosis of opioid toxicity. For pilot data, the investigators will also monitor use of opioids for analgesia at the 3-month postoperative time point as a secondary outcome.
This study assesses whether buprenorphine safely reduces full-agonist opioid use after orthopaedic surgery. Completion of the Aims of this study will permit future studies assessing whether buprenorphine comprises a less-addictive alternative for postoperative analgesia compared to full-agonist opioids. Annually, there are 40-50 million major surgeries performed in the US. As 6-7% of opioid-naïve patients develop long-term opioid use after major surgery, exploring avenues to decrease the impact of post-operative analgesia on the opioid epidemic is critical.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will be treated with the transdermal buprenorphine system (a transdermal patch) that is applied in the pre-operative holding area. Aside from being treated with the transdermal buprenorphine system, their care will otherwise be in accordance with the standard of care following ankle fracture surgery.
Drug: Buprenorphine Transdermal System
Participants in this arm will be treated with a placebo patch that is applied in the pre-operative holding area. Aside from the placebo patch, their care will otherwise be in accordance with the standard of care following ankle fracture surgery.
Drug: Placebo Patch
The buprenorphine transdermal system is unique from other interventions in the study, as it is the experimental drug in the study. The buprenorphine transdermal system will be applied in the pre-operative holding area. Aside from the buprenorphine transdermal system, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
The placebo patch is unique from other interventions in the study, as it is the placebo drug in the study. The placebo patch will be applied in the pre-operative holding area. Aside from the placebo patch, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.
Morphine Milligram Equivalents of Full-agonist Opioid Consumed
After surgery, patients will record the total amount of opioid medication they consumed during the first post-operative week in their pain diary. In admitted patients, the electronic medical record will be reviewed to determine the morphine milligram equivalents of opioid consumed while admitted. Patients will also bring all their bottles and opioid prescriptions to their first post-operative clinic visit, at which point their total opioid consumption between surgery and their first post-operative clinic visit will be recorded by the researchers.
Time frame: Post-operative days 0-7. First post-operative clinic visit (approximately 3 weeks after surgery).
Visual Analog Pain Scores
After surgery, visual analog pain scores with movement and at rest will be reported by the patient in a pain diary. In admitted patients, visual analog pain scores will be recorded by the bedside nurse. Visual analog pain scores are rated from 0-10. A score of 0 represents that the patient has no pain. A score of 10 represents excruciating pain.
Time frame: Postoperative days 1-8, 21, 90.
Morphine Milligram Equivalents of Full-Agonist Opioids Administered in Perioperative Setting
Review of the medication administration record will be performed to calculate the morphine milligram equivalents of opioid medication administered during ankle fracture surgery and in the post-operative recovery unit.
Time frame: Perioperative/Periprocedural
Adverse Effects Related to Opioid Medication
After surgery, patients will record whether they have symptoms of constipation, nausea, vomiting, drowsiness, or anything other symptoms potentially related to their opioid medication. The frequency and types of adverse effects will be recorded by the study researchers.
Time frame: Post-operative days 1-8, 21.
Hospital Readmissions due to Uncontrolled Post-operative Pain
The investigators will track the number of hospital readmissions due to uncontrolled post-operative pain.
Time frame: From patch application through post-operative day 21.
Emergency Department Presentations due to Uncontrolled Pain
The investigators will track the number of emergency department presentations, with a chief complaint of uncontrolled post-operative pain.
Time frame: From patch application through post-operative day 21.
Emergency Department Presentations due to Opioid Toxicity
The researchers will track the number of presentations to the emergency department with a chief complaint of opioid toxicity.
Time frame: From patch application to post-operative day 21
Hospital Readmissions due to Opioid Toxicity
The researchers will track the number of hospital readmissions secondary to opioid toxicity.
Time frame: From patch application to post-operative day 21
Time from Surgery Completion to Discharge
For patients undergoing outpatient surgery, review of the electronic medical record will be performed to determine the time from surgery completion to discharge.
Time frame: Perioperative/periprocedural
Hospital Length of Stay
For patients being admitted to the hospital to recover after ankle fracture surgery, review of the electronic medical record will be performed to determine the average hospital length of stay for each group.
Time frame: From the completion of ankle fracture surgery to hospital discharge.
Number of Breakthrough Pain Episodes while Inpatient
For patients admitted after surgery, the number of breakthrough pain episodes while inpatient will be determined. A breakthrough pain episode will be defined as a sudden, severe, brief pain occurring in the setting go f adequately controlled mild-moderate background pain. It will be denoted by the administration of a medication in the inpatient setting with an indication of "for breakthrough pain."
Time frame: Post-operative day 0 through hospital discharge
Quality of Recovery after Anesthesia 15-Question Survey
Patients will complete the quality of recovery after anesthesia 15-question survey. Scores range from 0 to 150. A score of 0 represents a poor recovery after anesthesia. A score of 150 represents an excellent recover after anesthesia.
Time frame: Post-operative day 7
Telephone Calls and MyChart Messages to Clinic or Call Center with a Chief Complaint of Uncontrolled Pain
Review of the electronic medical record will be performed to record the average number of telephone calls and MyChart messages to the orthopaedic surgery clinic or call center with a chief complaint of uncontrolled pain.
Time frame: Post-operative days 0-21.
Opioid Medication Prescriptions - Number and Total Morphine Milligram Equivalents Prescribed
The researchers will review the electronic medical record to record the number of opioid medication prescriptions requested and filled by the patient.
Time frame: From the time of injury through post-operative day 90.
Drug Liking and Economic Choice Survey
Patients will be asked by questionnaire how much they liked their buprenorphine vs placebo patch and oral narcotic prescriptions, as well as how much they would pay for their buprenorphine vs placebo patch and oral full-agonist opioid prescription.
Time frame: Post-operative days 7, 21, 90
Patient Satisfaction with Post-operative Pain Control
Patient satisfaction with their post-operative pain control will be recorded by questionnaire in the form of a Likert scale.
Time frame: Post-operative days 7, 21
Rate of Persistent Opioid Use
Approximately three months after surgery, patients will record whether they are continuing to take opioids/narcotics for pain related to their ankle fracture surgery.
Time frame: Post-operative day 90
Prescription Pain Medication Misuse Short Form 7a Scores
Patients will complete the PROMIS Prescription Pain Medication Misuse Short Form 7a. Scores will be tabulated from 0 to 35. A score of 35 represents a high level of pain medication misuse. A score of 0 represents a low level of pain medication misuse.
Time frame: Post-operative day 90
Post-operative Complication Rate
The researchers will review the electronic medical record to the rate and type of post-operative complications after ankle fracture surgery.
Time frame: Post-operative days 0-90
Plan to share: Yes — After deidentification, all individual participant data may be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning at the time of publication and ending 36 months after publication.
Access criteria: Deidentified participant data will be shared with other investigators based on any reasonable request, as deemed appropriate by the study team. Requests may be submitted to Noah Harrison at nharrison@wustl.edu for review. Link to data will be provided at the time of request approval.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 23 months is above that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buprenorphine